Ms. Qinghua Liu is Interim Chief Financial Officer, Director of Biostar Pharmaceuticals, Inc. She was appointed as Interim Chief Financial Officer of the Company effective as of December 18, 2012. Ms. Liu is currently a member of the Board of the Company. From January 2010 to present, Ms. Liu held the office of Assistant to the Chairman of the Board of the Company, Chief Financial Officer of Shaanxi Aoxing Pharmaceuticals Co., Ltd., and Supervisor of Shaanxi Biostar Biotech, Ltd. From March 2007 to January, Ms. Liu held the offices of Vice General Manager, Financial Manager, Chief Accountant and Director of Shaanxi Aoxing Pharmaceuticals Co., Ltd. From January 1998 to March 2007, she was Financial Manager and Chief Accountant of Shaanxi Aoxing Pharmaceuticals Co., Ltd. Ms. Liu holds a degree in Auditing and Financial Management from Northwest Institute of Light Industry, PRC.
Interim CFO and Director
Director Since 2012
The company has return on total asset (ROA) of (16.43) % which means that it has lost $16.43 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (29.81) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 4.76 M in liabilities with Debt to Equity (D/E) ratio of 0.08 which may suggest the company is not taking enough advantage from borrowing. Biostar Pharmaceuticals Inc has Current Ratio of 3.23 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Entity SummaryBiostar Pharmaceuticals, Inc. engages in the development, manufacture, and marketing of overthecounter and prescription pharmaceutical solutions for various diseases and conditions in the People?s Republic of China. Biostar Pharmaceuticals Inc [BSPM] is traded on NASDAQ General Markets in USA. It is located in Biostar Pharmaceuticals, Inc.Xianyang City, and employs 504 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| BSPM Nasdaq
Biostar Pharmaceuticals Inc
Currency: USD - US Dollar
Traded on NASDAQ General Markets
Biostar Pharmaceuticals Inc has less than 47.0 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Biostar price boundaries
Promote Biostar and Qinghua Liu